Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Recurrent chromosomal rearrangements have not been well characterized in common carcinomas. We used a bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of outlier gene expression. Two ETS transcription factors, ERG and ETV1 , were identified as outliers in prostate cancer. We identified recurrent gene fusions of the 5′ untranslated region of TMPRSS2 to ERG or ETV1 in prostate cancer tissues with outlier expression. By using fluorescence in situ hybridization, we demonstrated that 23 of 29 prostate cancer samples harbor rearrangements in ERG or ETV1 . Cell line experiments suggest that the androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS family members in prostate cancer. These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The high expression levels of ERG and PEA3 subfamily members in a subset of prostate tumors led to the discovery of common chromosomal rearrangements associated with this human cancer (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Chromosomal rearrangements that result in the overexpression of members of the PEA3 subfamily (ETV1, ETV4, or ETV5) are found less frequently (36, 170, 171).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Rearrangements of ETS loci are a hallmark of prostate cancer with ~50% of tumors showing alterations at an ETS gene locus (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Self-citationA census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Self-citationChromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R. (1982) · Nature · doi:10.1038/300765a0 · Cited by 1,378
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Research works printed but not linked: 5
- I. S. Jeon et al., Oncogene10, 1229 (1995).
- B. Lin et al., Cancer Res.59, 4180 (1999).
- D. E. Afar et al., Cancer Res.61, 1686 (2001).
- S. M. Dhanasekaran et al., FASEB J.19, 243 (2005).
- J. B. Welsh et al., Cancer Res.61, 5974 (2001).
Cited by
Items 401–500 of 1,014
Brase, J. C., Johannes, M., Mannsperger, H., Fälth, M., Metzger, J., Kacprzyk, L. A., Andrasiuk, T., Gade, S., Meister, M. A., Sirma, H., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-507 · Cited by 156
Evidence for field cancerization of the prostate
Nonn, L., Ananthanarayanan, V., & Gann, P. H. (2009) · The Prostate · doi:10.1002/pros.20983 · Cited by 151
Grand Challenges and Great Opportunities in Science, Technology, and Public Policy
Omenn, G. S. (2006) · Science · doi:10.1126/science.1135003 · Cited by 141
Garraway, I. P., Sun, W., Tran, C. P., Perner, S., Zhang, B., Goldstein, A. S., Hahm, S. A., Haider, M., Head, C. S., Reiter, R. E., et al. (2010) · The Prostate · doi:10.1002/pros.21083 · Cited by 145
Self-citationMertz, K. D., Setlur, S. R., Dhanasekaran, S. M., Demichelis, F., Perner, S., Tomlins, S. A., Tchinda, J., Laxman, B., Vessella, R. L., Beroukhimt, R., et al. (2007) · Neoplasia · doi:10.1593/neo.07103 · Cited by 160
Self-citationmiR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT
Kao, C.-J., Martiniez, A., Shi, X.-B., Yang, J. C., Evans, C. P., Dobi, A., White, R. D., & Kung, H.-J. (2013) · Oncogene · doi:10.1038/onc.2013.200 · Cited by 155
Urbanucci, A., Sahu, B., Seppälä, J., Larjo, A., Latonen, L., Waltering, K. K., Tammela, T. L. J., Vessella, R. L., Lähdesmäki, H. J., Jänne, O. A., et al. (2011) · Oncogene · doi:10.1038/onc.2011.401 · Cited by 155
“Nevertheless, only one AR target gene that is commonly involved in the development of the disease, TMPRSS2:ERG fusion gene, has so far been identified (Tomlins et al., 2005).”
BackgroundVitamin D Receptor Protein Expression in Tumor Tissue and Prostate Cancer Progression
Hendrickson, W. K., Flavin, R., Kasperzyk, J. L., Fiorentino, M., Fang, F., Lis, R. T., Fiore, C., Penney, K. L., Ma, J., Kantoff, P. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.9880 · Cited by 149
The Role of HOX Transcription Factors in Cancer Predisposition and Progression
Li, B., Huang, Q., & Wei, G. (2019) · Cancers · doi:10.3390/cancers11040528 · Cited by 163
Organoid based personalized medicine: from bench to bedside
Li, Y., Tang, P., Cai, S., Peng, J., & Hua, G. (2020) · Cell Regeneration · doi:10.1186/s13619-020-00059-z · Cited by 136
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics
Adamaki, M., & Zoumpourlis, V. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107932 · Cited by 157
Li, X., Baek, G., Ramanand, S. G., Sharp, A., Gao, Y., Yuan, W., Welti, J., Rodrigues, D. N., Dolling, D., Figueiredo, I., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.078 · Cited by 148
Chromosomal translocations: revisited yet again
Rowley, J. D. (2008) · Blood · doi:10.1182/blood-2008-04-097931 · Cited by 144
Lang, S., Frame, F. M., & Collins, A. T. (2008) · The Journal of Pathology · doi:10.1002/path.2478 · Cited by 181
The changing therapeutic landscape of castration-resistant prostate cancer
Yap, T. A., Zivi, A., Omlin, A. G., & Bono, J. S. D. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.117 · Cited by 159
Mészáros, B., Kumar, M., Gibson, T. J., Uyar, B., & Dosztányi, Z. (2017) · Science Signaling · doi:10.1126/scisignal.aak9982 · Cited by 141
Random forest-based modelling to detect biomarkers for prostate cancer progression
Tóth, R., Schiffmann, H., Hube‐Magg, C., Büscheck, F., Höflmayer, D., Weidemann, S. A., Lebok, P., Fraune, C., Minner, S. J. P., Schlomm, T., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0736-8 · Cited by 160
“These are both members of the erythroblast transformation-specific (ETS) transcription factor family along with ERG and commonly affected by gene fusions in PCa (Tomlins et al, 2006; Tomlins et al, 2005).”
BackgroundETS transcription factors in endocrine systems
Gutierrez‐Hartmann, A., Duval, D. L., & Bradford, A. P. (2007) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.03.002 · Cited by 148
Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia
Paulsson, K. M., Forestier, E., Lilljebjörn, H., Heldrup, J., Behrendtz, M., Young, B. D., & Johansson, B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006981107 · Cited by 146
Long, Q., Xu, J., Osunkoya, A. O., Sannigrahi, S., Johnson, B. A., Zhou, W., Gillespie, T. W., Park, J. Y., Nam, R. K., Sugar, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2699 · Cited by 146
Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance
Archer, M., Dogra, N., & Kyprianou, N. (2020) · Cancers · doi:10.3390/cancers12102984 · Cited by 159
“The presence of the TMPRSS2-ERG gene fusion may lead to more aggressive disease [35,36].”
BackgroundThe evolving biology and treatment of prostate cancer
Taichman, R. S., Loberg, R. D., Mehra, R., & Pienta, K. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31791 · Cited by 146
Self-citationCholesterol accumulation in prostate cancer: A classic observation from a modern perspective
Krycer, J. R., & Brown, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.01.002 · Cited by 166
Stegmaier, K., Wong, J. S., Ross, K. N., Chow, K. T., Peck, D., Wright, R. D., Lessnick, S. L., Kung, A. L., & Golub, T. R. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040122 · Cited by 143
Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
Chakravarty, D., Nair, S. S., Hammouda, N., Ratnani, P., Gharib, Y., Wagaskar, V., Mohamed, N., Lundon, D., Dovey, Z., Kyprianou, N., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-1088-9 · Cited by 143
Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer
Furusato, B., Gao, C., Ravindranath, L., Chen, Y., Cullen, J. C., McLeod, D. G., Dobi, A. L., Srivastava, S. K., Petrovics, G., & Sesterhenn, I. A. (2007) · Modern Pathology · doi:10.1038/modpathol.3800981 · Cited by 144
Tissue Microarrays in Clinical Oncology
Voduc, D. K., Kenney, C., & Nielsen, T. O. (2008) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2007.10.006 · Cited by 144
Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling
Pihlajamaa, P., Sahu, B., & Jänne, O. A. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1034 · Cited by 141
Genomic mechanisms and measurement of structural and numerical instability in cancer cells
Bayani, J., Selvarajah, S., Maire, G., Vukovic, B., Al-Romaih, K. I., Zieleńska, M., & Squire, J. A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.10.006 · Cited by 170
Kunderfranco, P., Mello-Grand, M., Cangemi, R., Pellini, S., Mensah, A., Albertini, V., Malek, A., Chiorino, G., Catapano, C. V., & Carbone, G. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010547 · Cited by 143
Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer
Leinonen, K. A., Saramäki, O. R., Furusato, B., Kimura, T., Takahashi, H., Egawa, S., Suzuki, H., Keiger, K., Hahm, S. H., Isaacs, W. B., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0333-t · Cited by 160
Oncogene-mediated alterations in chromatin conformation
Rickman, D. S., Soong, T. D., Moss, B., Mosquera, J. M., Dlabal, J., Terry, S., MacDonald, T. Y., Tripodi, J., Bunting, K., Najfeld, V., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112570109 · Cited by 134
Self-citationDrug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 158
Wang, J., Wen, S., Symmans, W. F., Pusztai, L., & Coombes, K. R. (2009) · Cancer Informatics · doi:10.4137/cin.s2846 · Cited by 142
Kakehi, Y., Sugimoto, M., & Taoka, R. (2017) · International Journal of Urology · doi:10.1111/iju.13380 · Cited by 146
Williamson, S. R., Zhang, S., Yao, J. L., Huang, J., Lopez-Beltran, A., Shen, S., Osunkoya, A. O., MacLennan, G. T., Montironi, R., & Cheng, L. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.56 · Cited by 140
Expression of ACE2, the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells
Song, H., Seddighzadeh, B., Cooperberg, M. R., & Huang, F. W. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.065 · Cited by 140
Wang, Q.-F., Wu, G., Mi, S., He, F., Wu, J., Dong, J., Luo, R. T., Mattison, R., Kaberlein, J. J., Prabhakar, S., et al. (2011) · Blood · doi:10.1182/blood-2010-12-324699 · Cited by 132
Lin, D. W., Newcomb, L. F., Brown, E. C., Brooks, J. D., Carroll, P. R., Feng, Z., Gleave, M. E., Lance, R. S., Sanda, M. G., Thompson, I. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3283 · Cited by 139
LUCAS, J., True, L. D., Hawley, S. J., Matsumura, M., Morrissey, C. M., Vessella, R. L., & Nelson, P. (2008) · The Journal of Pathology · doi:10.1002/path.2330 · Cited by 139
Hendriks, R. J., van Oort, I. M., & Schalken, J. A. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.59 · Cited by 139
Börno, S. T., Fischer, A., Kerick, M., Fälth, M., Laible, M., Brase, J. C., Kuner, R., Dahl, A., Grimm, C., Sayanjali, B., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0041 · Cited by 151
Self-citationProfiling Prostate Cancer Therapeutic Resistance
Wade, C. A., & Kyprianou, N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030904 · Cited by 147
Shrimp, J. H., Kales, S. C., Sanderson, P. E. J., Simeonov, A. M., Shen, M., & Hall, M. D. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00106 · Cited by 142
Li, Z., Tognon, C. E., Godinho, F. J., Yasaitis, L. C., Hock, H. R., Herschkowitz, J. I., Lannon, C. L., Cho, E., Kim, S., Bronson, R. T., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.012 · Cited by 143
Wang, G., Lunardi, A., Zhang, J., Chen, Z., Ala, U., Webster, K. A., Tay, Y., Gonzalez-Billalabeitia, E., Egia, A., Shaffer, D. R., et al. (2013) · Nature Genetics · doi:10.1038/ng.2654 · Cited by 137
Urine biomarkers in prostate cancer
Ploussard, G., & TAILLE, A. D. L. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2009.261 · Cited by 153
Huang, W., Hennrick, K. T., & Drew, S. A. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.05.009 · Cited by 137
Androgen Regulation of the TMPRSS2 Gene and the Effect of a SNP in an Androgen Response Element
Clinckemalie, L., Spans, L., Dubois, V., Laurent, M., Helsen, C., Joniau, S., & Claessens, F. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1098 · Cited by 136
Kamel, H. F. M., & Al-Amodi, H. S. A. B. (2017) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.11.005 · Cited by 157
The current state of preclinical prostate cancer animal models
Pienta, K. J., Abate-Shen, C. T., Agus, D. B., Attar, R. M., Chung, L. W. K., Greenberg, N. M., Hahn, W. C., Isaacs, J. T., Navone, N. M., Peehl, D. M., et al. (2008) · The Prostate · doi:10.1002/pros.20726 · Cited by 148
Self-citationProstate cancer genomics: towards a new understanding
Witte, J. S. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2507 · Cited by 158
Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers
Filella, X., & Foj, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111784 · Cited by 149
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations
Huang, F. W., Mosquera, J. M., Garofalo, A., Oh, C., Baco, M. B., Amin‐Mansour, A., Rabasha, B., Bahl, S., Mullane, S. A., Robinson, B. D., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0960 · Cited by 142
Self-citationCell surface–anchored serine proteases in cancer progression and metastasis
Martin, C. E., & List, K. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09811-7 · Cited by 147
Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies
Lee, J.-K., Choi, Y.-L., Kwon, M., & Park, P. J. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044446 · Cited by 135
John, J. S., Powell, K., & Conley‐LaComb, M. K. (2012) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000119 · Cited by 153
Molecular Pathogenesis and Progression of Prostate Cancer
Schrecengost, R. S., & Knudsen, K. E. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.04.001 · Cited by 159
Aytés, À., Mitrofanova, A., Kinkade, C. W., Lefèbvre, C., Lei, M., Phelan, V., Lekaye, C., Koutcher, J. A., Cardiff, R. D., Califano, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303558110 · Cited by 153
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair
Shafi, A. A., McNair, C. M., McCann, J. J., Alshalalfa, M., Shostak, A., Severson, T., Zhu, Y., Bergman, A. M., Gordon, N., Mandigo, A. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20513-5 · Cited by 143
Lapointe, J., Kim, Y. H., Miller, M. A., Li, C., Kaygusuz, G., van de Rijn, M., Huntsman, D. D., Brooks, J. D., & Pollack, J. R. (2007) · Modern Pathology · doi:10.1038/modpathol.3800759 · Cited by 140
Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis
Ramsay, A. J., Hooper, J. D., Folgueras, A. R., Velasco, G., & López-Otín, C. (2009) · Haematologica · doi:10.3324/haematol.2008.001867 · Cited by 143
Metzeler, K. H., Dufour, A. M., Benthaus, T., Hummel, M., Sauerland, M., Heinecke, A., Berdel, W. E., Büchner, T., Wormann, B. J., Mansmann, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5328 · Cited by 154
Armstrong, A. J., Tannock, I. F., de Wit, R., George, D. J., Eisenberger, M. A., & Halabi, S. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.11.007 · Cited by 138
Cohen, R. J., Wheeler, T. M., Bonkhoff, H., & Rubin, M. A. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-1103-apotih · Cited by 137
Self-citationThe role of type II transmembrane serine protease‐mediated signaling in cancer
Tanabe, L. M., & List, K. (2016) · FEBS Journal · doi:10.1111/febs.13971 · Cited by 132
Meisenberg, C., Pinder, S. I., Hopkins, S. R., Wooller, S. K., Benstead-Hume, G., Pearl, F. M. G., Jeggo, P. A., & Downs, J. A. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.11.001 · Cited by 140
“, 2009; Figures 5D and 5E), and this translocation event is frequently present in prostate cancers (Tomlins et al., 2005).”
BackgroundThind, A. S., Monga, I., Thakur, P. K., Kumari, P., Dindhoria, K., Krzak, M., Ranson, M., & Ashford, B. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab259 · Cited by 129
Amyloid Precursor Protein Is a Primary Androgen Target Gene That Promotes Prostate Cancer Growth
Takayama, K., Tsutsumi, S., Suzuki, T., Horie‐Inoue, K., Ikeda, K., Kaneshiro, K., Fujimura, T., Kumagai, J., Urano, T., Sakaki, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-3633 · Cited by 138
N-myc Downstream Regulated Gene 1 (NDRG1) Is Fused to ERG in Prostate Cancer
Pflueger, D., Rickman, D. S., Sboner, A., Perner, S., Lafargue, C. J., Svensson, M. A., Moss, B. J., Kitabayashi, N., Pan, Y., TAILLE, A. D. L., et al. (2009) · Neoplasia · doi:10.1593/neo.09572 · Cited by 132
Self-citationIndividual-level analysis of differential expression of genes and pathways for personalized medicine
Wang, H., Sun, Q., Zhao, W., Qi, L., Gu, Y., Li, P., Zhang, M., Li, Y., Liu, S., & Guo, Z. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu522 · Cited by 132
TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers
Hägglöf, C., Hammarsten, P., Strömvall, K., Egevad, L., Josefsson, A., Stattin, P. E., Granfors, T., & Bergh, A. R. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086824 · Cited by 143
ERG induces taxane resistance in castration-resistant prostate cancer
Galletti, G., Matov, A., Beltran, H., Fontugne, J., Mosquera, J. M., Cheung, C., MacDonald, T. Y., Sung, M. S., O'Toole, S. A., Kench, J. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6548 · Cited by 138
Self-citationNguyen, L. T., Tretiakova, M. S., Silvis, M. R., Lucas, J., Klezovitch, O., Coleman, I., Bolouri, H., Kutyavin, V. I., Morrissey, C., True, L. D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.005 · Cited by 123
Snoek, R., Cheng, H., Margiotti, K., Wafa, L. A., Wong, C. A., Wong, E. C., Fazli, L., Nelson, C. C., Gleave, M. E., & Rennie, P. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1726 · Cited by 131
Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer
Wang, S., Kollipara, R. K., Srivastava, N., Li, R., Ravindranathan, P., Hernández, E., Freeman, E., Humphries, C. G., Kapur, P., Lotan, Y., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322198111 · Cited by 136
“Fusions of E-twentysix (ETS) transcription factor genes with androgen-responsive genes (2), mainly transmembrane protease, serine 2 (TMPRSS2), are present in up to 80% of prostate cancers.”
BackgroundBiomarkers in prostate cancer surveillance and screening: past, present, and future
Cary, C., & Cooperberg, M. R. (2013) · Therapeutic Advances in Urology · doi:10.1177/1756287213495915 · Cited by 145
Morphological features of TMPRSS2–ERG gene fusion prostate cancer
Mosquera, J. M., Perner, S., Demichelis, F., Kim, R., Hofer, M. D., Mertz, K. D., Paris, P., Simko, J., Collins, C. C., Bismar, T., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2154 · Cited by 144
Self-citationA genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study
Murabito, J. M., Rosenberg, C. L., Finger, D., Kreger, B. E., Levy, D. A., Splansky, G. L., Antman, K. H., & Hwang, S. (2007) · BMC Medical Genetics · doi:10.1186/1471-2350-8-s1-s6 · Cited by 132
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor
Scheble, V. J., Braun, M., Beroukhim, R., Mermel, C. H., Ruiz, C. F., Wilbertz, T., Stiedl, A., Petersen, K., Reischl, M., Kuefer, R., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.87 · Cited by 131
Self-citationClinical variability and molecular heterogeneity in prostate cancer
Barbieri, C. E., & Shoag, J. E. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.178852 · Cited by 142
The role of GATA2 in lethal prostate cancer aggressiveness
Rodríguez-Bravo, V., Carceles‐Cordon, M., Hoshida, Y., Cordon‐Cardo, C., Galsky, M. D., & Domenech, J. M. D. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.225 · Cited by 145
Homozygous Deletions and Recurrent Amplifications Implicate New Genes Involved in Prostate Cancer
Liu, W., Xie, C. C., Zhu, Y., Li, T., Sun, J., Cheng, Y., Ewing, C. M., Dalrymple, S., Turner, A. R., Sun, J., et al. (2008) · Neoplasia · doi:10.1593/neo.08428 · Cited by 126
Hampton, O. A., Den Hollander, P., Miller, C. A., Delgado, D. A., Li, J., Coarfa, C., Harris, R. A., Richards, S., Scherer, S. E., Muzny, D. M., et al. (2009) · Genome Research · doi:10.1101/gr.080259.108 · Cited by 129
“(Tomlins et al. 2005).”
Toward the Detection of Prostate Cancer in Urine: A Critical Analysis
Truong, M., Yang, B., & Jarrard, D. F. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.04.143 · Cited by 127
Dissanayake, K., Toth, R. L., Blakey, J., Olsson, O., Campbell, D. G., Prescott, A. R., & MacKintosh, C. (2011) · Biochemical Journal · doi:10.1042/bj20101562 · Cited by 139
USP22 regulates oncogenic signaling pathways to drive lethal cancer progression
Schrecengost, R. S., Dean, J. L., Goodwin, J. F., Schiewer, M. J., Urban, M. W., Stanek, T. J., Sussman, R. T., Hicks, J. L., Birbe, R. C., Draganova-Tacheva, R. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1954 · Cited by 126
Fusion genes and chromosome translocations in the common epithelial cancers
Edwards, P. A. (2010) · The Journal of Pathology · doi:10.1002/path.2632 · Cited by 126
Leshem, O., Madar, S., Kogan-Sakin, I., Kamer, I., Goldstein, I., Brosh, R., Cohen, Y., Jacob‐Hirsch, J., Ehrlich, M., Ben‐Sasson, S. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021650 · Cited by 136
Chromoplexy: A New Category of Complex Rearrangements in the Cancer Genome
Shen, M. M. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.025 · Cited by 123
“Prostate cancer was the first solid tumor shown to have frequent largescale chromosomal rearrangements, as originally demonstrated by the discovery of the TMPRSS2-ERG fusion (Tomlins et al., 2005).”
BackgroundAmin, M. B., Lin, D. W., Gore, J. L., Srigley, J. R., Samaratunga, H., Egevad, L., Rubin, M., Nacey, J., Carter, H. B., Klotz, L., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2014-0219-sa · Cited by 124
Self-citationZhang, X., Choi, P. S., Francis, J. M., Gao, G. F., Campbell, J. D., Ramachandran, A., Mitsuishi, Y., Ha, G., Shih, J., Vazquez, F., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0532 · Cited by 126
Litvinov, I. V., Griend, D. J. V., Antony, L., Dalrymple, S. L., Marzo, A. M. D., Drake, C. G., & Isaacs, J. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603057103 · Cited by 126
Krohn, A., Seidel, A., Burkhardt, L., Bachmann, F., Mäder, M., Grupp, K., Eichenauer, T., Becker, A., Adam, M., Graefen, M., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4223 · Cited by 130
Miller, C. A., Settle, S. H., Sulman, E. P., Aldape, K. D., & Milosavljevic, A. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-34 · Cited by 126
ERG Is a Megakaryocytic Oncogene
Salek-Ardakani, S., Smooha, G., de Boer, J., Sebire, N. J., Morrow, M., Rainis, L., Lee, S., Williams, O., Izraeli, S., & Brady, H. J. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0075 · Cited by 120
Albino, D., Longoni, N., Curti, L., Grand, M. M., Pinton, S., Civenni, G., Thalmann, G. N., D’Ambrosio, G., Sarti, M., Sessa, F., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0212 · Cited by 142
Chuang, T., Wu, C.-S., Chen, C.-Y., Hung, L.-Y., Chiang, T.-W., & Yang, M.-Y. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1013 · Cited by 130
Significance of the TMPRSS2:ERG gene fusion in prostate cancer
Wang, Z., Wang, Y., Zhang, J., Hu, Q., Zhi, F., Zhang, S., Mao, D., Zhang, Y., & Liang, H. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7281 · Cited by 141
Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance
Chen, F., Long, Q., Fu, D., Zhu, D., Ji, Y., Han, L., Zhang, B., Xu, Q., Liu, B., Li, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06860-4 · Cited by 122
Metadata
- Authors
- Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109–0602, USA.
- Corresponding author
- Chinnaiyan, Arul M.
- ORCID
- Venue
- Science
- Published
- 2005-10-28
- Volume
- 310
- Issue
- 5748
- Pages
- 644-648
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2121158863
- Cited by
- 3,846
- References
- 32
- Citations by year
- 2026: 77 · 2025: 99 · 2024: 82 · 2023: 108 · 2022: 137 · 2021: 163 · 2020: 187 · 2019: 172 · 2018: 178 · 2017: 218 · 2016: 209 · 2015: 244 · 2014: 271 · 2013: 309 · 2012: 279
- FWCI
- 114.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG021404, R01 AG 21404)
- National Cancer Institute (UO1 CA111275-01, P50-CA-69568, U01CA111275, R01CA097063, R01 CA97063, 5P30 CA 46592, P50CA069568, P30CA046592)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- TMPRSS2-ERG fusion, prostate cancer, ETS transcription factors, chromosomal rearrangements, gene fusion, molecular diagnosis
- MeSH terms
- Transcriptional Regulator ERG, Androgens, DNA-Binding Proteins, Humans, Male, Membrane Proteins, Molecular Sequence Data, Neoplasm Proteins, Prostatic Neoplasms, Serine Endopeptidases, Transcription Factors, Translocation, Genetic, Gene Rearrangement, Oncogene Proteins, Fusion, Trans-Activators, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, In Situ Hybridization, Fluorescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.